Figure 1.
Figure 1. Prognostic significance for interphase and metaphase results. (A) Estimated relative risk of death (—), along with 95% confidence intervals (-/-/-), for patients with various percentages of abnormal interphase nuclei. Estimated risk is relative to the total set of patients in the study; hence the average risk is 1. Vertical marks on the x-axis correspond to observed data. (B) Patients with greater than 50% abnormal interphase nuclei have poor survival. (C) Abnormal metaphase cells are associated with poor survival. (D) Anomalies of chromosome 13q in metaphase cells is a poor prognosis, but not when seen in interphase cells (IFISH). (E) A hierarchy of chromosome anomalies in metaphase cells is useful to stratify patients into prognostic groups. (F) A hierarchy of chromosome anomalies in interphase cells is useful to stratify patients into prognostic groups. Abn indicates abnormal; norm, normal; MS, median survival.

Prognostic significance for interphase and metaphase results. (A) Estimated relative risk of death (—), along with 95% confidence intervals (-/-/-), for patients with various percentages of abnormal interphase nuclei. Estimated risk is relative to the total set of patients in the study; hence the average risk is 1. Vertical marks on the x-axis correspond to observed data. (B) Patients with greater than 50% abnormal interphase nuclei have poor survival. (C) Abnormal metaphase cells are associated with poor survival. (D) Anomalies of chromosome 13q in metaphase cells is a poor prognosis, but not when seen in interphase cells (IFISH). (E) A hierarchy of chromosome anomalies in metaphase cells is useful to stratify patients into prognostic groups. (F) A hierarchy of chromosome anomalies in interphase cells is useful to stratify patients into prognostic groups. Abn indicates abnormal; norm, normal; MS, median survival.

Close Modal

or Create an Account

Close Modal
Close Modal